



RESEARCH ARTICLE

Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA [version 1; referees: 2 approved]

Gerhard J. Molderings ¹, Thomas Zienkiewicz², Jürgen Homann³, Markus Menzen³, Lawrence B. Afrin⁴

¹Institute of Human Genetics, University Hospital of Bonn, Bonn, D-53127, Germany

²Institute of Pathology Bonn-Duisdorf, Bonn, D-53123, Germany

³Division of Internal Medicine, Department of Gastroenterology and Diabetology, Gemeinschaftskrankenhaus Bonn, Bonn, D-53113, Germany

⁴Armonk Integrative Medicine, Armonk, NY, 10504, USA

v1 First published: 26 Oct 2017, 6:1889 (doi: [10.12688/f1000research.12730.1](https://doi.org/10.12688/f1000research.12730.1))
 Latest published: 26 Oct 2017, 6:1889 (doi: [10.12688/f1000research.12730.1](https://doi.org/10.12688/f1000research.12730.1))

Abstract

Background: It has been shown repeatedly that mast cells can promote or prevent cancer development and growth. If development and/or progression of a solid cancer is substantially influenced by mast cell activity, the frequencies of occurrence of solid cancers in patients with primary mast cells disorders would be expected to differ from the corresponding prevalence data in the general population. In fact, a recent study demonstrated that patients with systemic mastocytosis (i.e., a rare neoplastic variant of the primary mast cell activation disease) have increased risk for solid cancers, in particular melanoma and non-melanoma skin cancers. The aim of the present study is to examine whether the risk of solid cancer is increased in systemic mast cell activation syndrome (MCAS), the common systemic variant of mast cell activation disease.

Methods: In the present descriptive study, we have analysed a large (n=828) patient group with MCAS, consisting of cohorts from Germany and the USA, for occurrence of solid forms of cancer and compared the frequencies of the different cancers with corresponding prevalence data for German and U.S. general populations.

Results: Sixty-eight of the 828 MCAS patients (46 female, 22 male) had developed a solid tumor before the diagnosis of MCAS was made. Comparison of the frequencies of the malignancies in the MCAS patients with their prevalence in the general population revealed a significantly increased prevalence for melanoma and cancers of the breast, cervix uteri, ovary, lung, and thyroid in MCAS patients.

Conclusions: Our data support the view that mast cells may promote development of certain malignant tumors. These findings indicate a need for increased surveillance of certain types of cancer in MCAS patients irrespective of its individual clinical presentation.

Open Peer Review

Referee Status: 

	Invited Referees	
	1	2
version 1 published 26 Oct 2017	 report	 report
1 Bastian Walz , Klinik für Innere Medizin, Rheumatologie und Immunologie, Germany		
2 Leonard B. Weinstock , Washington University School of Medicine, USA		

Discuss this article

Comments (0)

Corresponding author: Gerhard J. Molderings (molderings@uni-bonn.de)

Author roles: **Molderings GJ:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Validation, Writing – Original Draft Preparation; **Zienkiewicz T:** Investigation, Validation, Writing – Original Draft Preparation; **Homann J:** Conceptualization, Investigation, Writing – Original Draft Preparation; **Menzen M:** Conceptualization, Data Curation, Project Administration; **Afrin LB:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Validation, Writing – Original Draft Preparation

Competing interests: No competing interests were disclosed.

How to cite this article: Molderings GJ, Zienkiewicz T, Homann J *et al.* **Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA [version 1; referees: 2 approved]** *F1000Research* 2017, **6**:1889 (doi: [10.12688/f1000research.12730.1](https://doi.org/10.12688/f1000research.12730.1))

Copyright: © 2017 Molderings GJ *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Grant information: Publication was supported by the Förderclub Mastzellforschung e.V., Germany. Collection of the U.S. data was supported by The Mastocytosis Society.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

First published: 26 Oct 2017, **6**:1889 (doi: [10.12688/f1000research.12730.1](https://doi.org/10.12688/f1000research.12730.1))

Introduction

Systemic mast cell activation disease (MCAD) comprises a heterogeneous group of multifactorial polygenic disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and mast cell leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] or well-differentiated systemic mastocytosis; [Table 1](#); for details, see [1](#)). The various MCAD classes and clinical subtypes represent varying manifestations of a common process of MC dysfunction²⁻⁵ (for details, see [Supplementary File 1](#)). While the prevalence of SM in Europeans ranges between 0.3 and 13 per 100,000⁶⁻⁸, the prevalence for MCAS may be in the single-digit percentage range (at least in Germany⁹).

MCs are best known for their effector functions in IgE-associated allergic reactions, but they are also involved in a variety of processes maintaining homeostasis or contributing to disease. Studies have shown that MCs accumulate in tumors and their microenvironment, inferring potential for influencing tumor development, tumor-induced angiogenesis, tissue remodeling, and shaping of adaptive immune responses to tumors by release of certain subsets of mediators (e.g., EGF, NGF, PDGF, SCF, angiopoietin, heparin, IL-8, VEGF). Increased accumulation of MCs within tumor environments has been correlated with poor prognosis, increased metastasis, and reduced survival in several types of human cancer, including melanoma¹⁰⁻¹², prostate carcinoma¹³, pancreatic adenocarcinoma¹⁴, squamous cell carcinomas of the esophagus¹⁵, mouth¹⁶, and lip¹⁷, and Merkel cell carcinoma¹⁸. Conflicting findings have been reported for lung adenocarcinoma and breast carcinomas: increased numbers of MCs have been shown to correlate with either a good¹⁹⁻²¹ or poor^{22,23} prognosis in non-small cell lung cancer. In breast carcinomas, most²⁴⁻²⁷ but not all^{28,29} studies have linked increased MC density to a good prognosis. For prostate cancer and colorectal cancer, MC densities within the tumors seem to be an independent favorable prognostic factor³⁰⁻³⁵, whereas high numbers of peritumoral MCs were associated with a poor prognosis^{36,37}.

Tumorigenic effects of MCs could be pronounced in MCAD, which is characterized by an increased systemic density and activity

of MCs. Knowledge of increased risk for cancer in patients with MCAD would first have important implications for counseling and care of these patients and second would support the idea of an involvement of MCs in tumorigenesis. In fact, a recent study demonstrated that SM patients bear increased risk for solid cancers, in particular melanoma and non-melanoma skin cancers³⁸. However, studies of occurrence of solid cancer in the proportionally prevalent MCAD patient group with MCAS patients have not yet been performed. Therefore, the aim of the present study was to analyze a large MCAS patient group, consisting of two roughly equally sized cohorts from Germany and the USA retrospectively, for the occurrence of solid cancers and to compare their frequencies with corresponding prevalences in German and U.S. general populations.

Methods

Diagnostic procedures

MCAS was diagnosed per current provisional criteria (for detailed discussion of the criteria, see [Supplementary File 1: Table S2](#)). For differential diagnosis, other diseases presenting similar symptoms were ruled out by appropriate assessments, including laboratory testing, imaging, and/or endoscopy. Occurrence of solid cancer was determined from the medical history obtained at the time MCAS was diagnosed. Due to the retrospective character of the study, pathological material of the solid malignancy could not be specifically stained for MCs. Since in MCAD the profile of MC mediator elevations is highly dependent on individual conditions, correlation analysis of mediator levels determined as part of MCAS diagnosis and the occurrence of specific tumor types was not performed.

Patient characteristics

German MCAS patients. 417 Caucasians presented consecutively to the *Bonn Interdisciplinary Research Group for Systemic Mast Cell Diseases* between May 2005 and May 2016 for diagnostic evaluation, and were assigned a diagnosis of MCAS diagnosed per current criteria ([39](#), [Table S2](#)). These patients were included in this retrospective study. The presence of MCAS was the only inclusion criterion; there were no exclusion criteria. From the patients' clinical files, data concerning the occurrence of solid tumors and hematologic neoplasms up to the time of the presentation at our research group were extracted. All data in this study were collected during routine clinical evaluations of MCAS patients who provided informed consent for use of such data in research. Patient information was anonymized prior to analysis. As such, the Ethics Committee of the Medical Faculty of the University of Bonn classified this study as exempt from requiring specific patient consent. This committee also approved the protocol for this study.

The frequencies of solid cancers in the German MCAS patient cohort were compared with the 10-year prevalences of these cancers in the general German population⁴⁰.

U.S. MCAS patients. The full population of 411 U.S. patients included in this study was comprised of a 296 patient population examined retrospectively (protocol Pro00015852, diagnoses made between November 2008 and September 2012 per current criteria

Table 1. Classification of systemic mast cell activation disease.

Systemic mast cell activation disease (MCAD)		
Classes	Systemic mastocytosis (SM)	Systemic mast cell activation syndrome (MCAS)
Subtypes	indolent SM smoldering SM aggressive SM SM with associated hematologic neoplasm mast cell leukemia	with hypertryptasemia without hypertryptasemia

(Table S2)) and a 115 patient population examined prospectively (protocol Pro00015857, diagnoses made between April 2012 and October 2013 per current criteria (Table S2)) at a single center (the Medical University of South Carolina). Protocols were approved by the center's institutional review board (IRB); the retrospective protocol was deemed IRB-exempt, and all prospective subjects provided written informed consent. Eligible patients for the retrospective protocol were all living, and deceased adult (18 years or older) patients who were, or had been, diagnosed with MCAS from the first such diagnosis at MUSC to the opening of the protocol; the accrual goal for the prospective protocol (targeting adult patients clinically suspected of having MCAS and undergoing diagnostic testing for such, and primarily designed to assess differences in monocyte growth factors between MCAS patients with monocytosis vs. healthy control subjects) was set based on expectations (derived from preliminary data) of finding monocytosis in 70% of MCAS patients.

Retrospective patients were identified through interrogation of the MUSC enterprise data warehouse for patients diagnosed with MCAS; the subjects' medical records at MUSC served as the sole source of data for the study, and no patient was contacted to obtain additional information. Prospective patients were identified in the course of the principal investigator's (LBA's) clinical work and provided written informed consent. All diagnoses met published criteria³⁹ and were made at age 16 or older. Data items abstracted from eligible patients' medical records included gender, race, age, symptoms, comorbidities, date of MCAS diagnosis, and all

results on file of routine complete blood counts, routine chemistry panels, and diagnostic testing for MCAS per published criteria.

The frequencies of solid cancers in the U.S. MCAS patient cohort were compared with the 32-year prevalences of these cancers in the general U.S. population (from Cancer Statistics Review 1975–2013; all races)⁴¹.

Statistical analysis

Our MCAS patient cohorts were not corrected for cancer risk factors, such as smoking, alcohol intake and body mass index, since the data for the German and U.S. population that were used for comparison were also not corrected in that way. Due to the retrospective nature of the study, we could only calculate the prevalence of a given tumor from the medical histories of the patients, not its incidence. Therefore, standardized incidence ratios could not be calculated and differences between the frequencies of tumor occurrence in our patient groups and the corresponding prevalences in the German and U.S. general population were analyzed by means of two-sided χ^2 test using GraphPad InStat V3.05. Here, a significance level of $\alpha=0.05$ was set.

Results

Characteristics of the study population

The 828 MCAS patients included in the study showed male:female ratios of about 1:2.5 in both population groups, which did not differ significantly in age distribution (Table 2). Forty-four MCAS patients had additional associated hematologic neoplasms,

Table 2. Characteristics of the study population, including demographics and associated hematologic neoplasms.

German MCAS study group (n=417)	
Male (n=105)	Female (n=312)
male to female ratio: 1:2.9	
Age [years]: mean \pm SD, median, range	
45.7 \pm 17.1, 46, 12–86	49.7 \pm 14.8, 50, 15–85
Plasmacytoma (n=1) Chronic lymphocytic leukemia (n=1)	
U.S. MCAS study group (n=411)	
Male (n=125)	Female (n=286)
Male to female ratio: 1:2.3	
Age [years]: mean \pm SD, median, range	
54.9 \pm 17.1, 43, 21–96	53.6 \pm 17.5, 54, 20–96
Chronic lymphocytic leukemia (n=3) Non-Hodgkin's lymphoma (n=2) Hodgkin's lymphoma (n=2) Multiple myeloma (n=6) Acute leukemia (n=2) JAK2-positive essential thrombocytosis (n=4)	Chronic lymphocytic leukemia (n=5) Non-Hodgkin's lymphoma (n=2) Multiple myeloma (n=6) Acute leukemia (n=2) JAK2-positive essential thrombocytosis (n=8)

MCAS, systemic mast cell activation syndrome; SD, standard deviation.

most frequently multiple myeloma, JAK2-positive essential thrombocytosis, and chronic lymphocytic leukemia (Table 2). In these patients there was no comorbidity of a solid cancer.

Prevalence of solid malignant diseases in the MCAS patients

German patient group. Eighteen of 417 MCAS patients (15 female, 3 male) had developed a solid tumor before the diagnosis of MCAS was made (Table 3). The most frequent tumor was breast cancer in eight patients (Table 3). The comparison of the frequencies of the malignancies in the MCAS patients with their 10-year prevalence in the German general population revealed in subsets of the MCAS patients a significantly increased prevalence for melanoma ($P<0.001$), lung cancer ($P<0.0001$), breast cancer

($P<0.003$), cervical carcinoma ($P<0.0001$), cancer of the urinary bladder ($P<0.03$) and testis ($P=0.05$) (Table 3).

US patient group. Sixty-three of the 411 MCAS patients had developed a solid tumor before the diagnosis of MCAS was made (Table 4), 47 female and 16 male patients. The difference to the numbers of solid tumors listed in Table 4 is due to the fact that some patients had more than one solid tumor. The most frequent tumors were non-melanoma skin cancer and breast cancer (Table 4). The comparison of the frequencies of the malignancies in the MCAS patients with their 32-year prevalence in the U.S. general population revealed in subsets of the MCAS patients a significantly increased prevalence for lung cancer ($P<0.0001$), cervical uterine carcinoma ($P<0.0001$), ovarian cancer ($P<0.02$),

Table 3. Comparison of the frequencies of solid cancers in the German MCAS patient cohort with the 10-year prevalences of these cancers in the general German population⁴⁰.

Malignant diseases of the	10-year prevalence in German population	MCAS patients; n=417
Skin: melanoma	f, age 0–39 years : 0.06% f, age > 39 years: 0.19% m, age 0–49 years: 0.05% m, age >49 years: 0.21%	(n= 79) 0 (n=233) 1 = 0.43%, $P=0.611$, ns (n=60) 1 = 1.67%, $P=0.0001$ (n=45) 0
Lung	f, age 0–49 years : 0.01% f, age > 49 years: 0.13% m, age 0–49 years: 0.01% m, age >49 years: 0.47%	(n=139) 1 = 0.72%, $P<0.0001$ (n=173) 0 (n=60) 0 (n=45) 0
Stomach	f, age 0–69 years: 0.05% f, age > 69 years: 0.26% m, age 0–59 years: 0.05% m, age > 59 years: 0.38%	(n=283) 0 (n=28) 0 (n=83) 0 (n=23) 0
Gut	f,m, age 0–59: 0.15% f,m, age > 59 years: 1.5%	(n=323) 0 (n=94) 0
Carcinoid	f,m	f: 0.7% 2
Breast	0–39 years: < 0.01% > 39 years: 1.7%	(n=79) 1 = 1.3%, $P=0.0025$ (n=233) 7 = 3.00%, $P=0.0019$
Uterus: cervix	0–39 years: 0.04% > 39 years: 0.16%	(n=79) 1 = 1.30%, $P<0.0001$ (n=233) 1 = 0.43%; $P=0.4613$, ns
body	0-39 years: 0.05% > 39 years: 0.57%	(n=79) 0 (n=233) 0
Prostate	age 0–59 years: 0.1% age >59 years: 4.2%	(n=82) 0 (n=23) 0
Testis	0–39 years: 0.11% > 39 years: 0.09%	(n=42) 1 = 2.4%, $P=0.050$ (n=63)
Urinary bladder	f, age 0–59 years: 0.02% f, age > 59 years: 0.31% m, age 0–59 years: 0.05% m, age > 59 years: 1.68%	(n=236) 1 = 0.42%, $P=0.022$ (n=76) 0 (n=82) 0 (n=23) 0
Thyroid gland	F, all ages : 0.10% M, all ages: 0.32%	(n=312) 0 (n=105) 1 = 0.2%, $P=0.7780$, ns

Parentheses, number of patients in the respective age group; bold print, number of affected patients; f, female; m, male. P, two-sided P value in the Chi-square-test; ns, not significant

Table 4. Comparison of the frequencies of solid cancers in the U.S. MCAS patient cohort with the 32-year prevalences of these cancers in the general U.S. population (from Cancer Statistics Review 1975–2013; all races)⁴¹.

Malignant diseases of the	32-year prevalence in the U.S. population	MCAS patients; n=411
Skin: melanoma	f, age 0–39 years: 0.042% f, age > 39 years: 0.418% m, age 0–49 years: 0.022% m, age >49 years: 0.681%	(n= 69) 0 (n=218) 1 = 0.46%, ns (n=49) 0 (n=77) 1 = 1.30%, ns
Skin: basal cell and squamous cell carcinoma	f, m, all ages: 0.63% ¹	(n=411) 14 [7 BCC] = 1.70%
Lung	f, age 0–49 years : 0.009% f, age > 49 years: 0.422% m, age 0–49 years: 0.005% m, age >49 years: 0.444%	(n=119) 2 = 1.68%, P<0.0001 (n=168) 3 = 1.19%, ns (n=49) 0 (n=77) 0
Mesothelium	f, m, all ages: 0.001%	(n=411) 1 = 0.24%
Stomach	f, age 0–69 years: 0.018% f, age > 69 years: 0.120% m, age 0–59 years: 0.014% m, age > 59 years: 0.166%	(n=228) 0 (n=59) 0 (n=73) 0 (n=53) 0
Gut: carcinoma	f,m, age 0–59: 0.10% f,m, age > 59 years: 1.54%	(n=251) 0 (n=162) 3 = 1.23%, ns
Liver	f,m, age 0–39: 0.002% f,m, age > 39 years: 0.05%	(n=94) (n=319) 1 = 0.31%, ns
Breast	0–39 years: 0.01% > 39 years: 2.68%	(n=69) 0 (n=218) 10 = 4.59%, ns
Uterus: cervix	0–39 years: 0.03% > 39 years: 0.17%	(n=69) 0 (n=218) 5 = 2.29%, P<0.0001
body	0–39 years: 0.03% > 39 years: 0.76%	(n=69) 0 (n=218) 4 = 1.84%, ns
Ovary	0–39 years: 0.015% > 39 years: 0.184%	(n=69) (n=218) 1 = 0.46%, P=0.0192
Vulva	epidemiological data not available	f 74 ys, f 69 ys
Prostate	age 0–59 years: 0.272% age >59 years: 10.608%	(n=73) 0 (n=53) 5 = 9.43%, ns
Testis	0–39 years: 0.0063% > 39 years: 0.099%	(n=25) 0 (n=101) 0
Urinary bladder	f, age 0–59 years: 0.011% f, age > 59 years: 0.344% m, age 0–59 years: 0.037% m, age > 59 years: 1.442%	(n=178) 0 (n=109) 2 = 1.84%, ns (n=73) 0 (n=53) 3 = 5.66%, P=0.0346
Thyroid gland	f, all ages : 0.215% m, all ages: 0.062%	(n=287) 5 = 1.39%, P=0.0057 (n=126) 1 = 0.79%, ns
Carcinoid	epidemiological data not available	f 29 ys, f 75ys
Sarcoma	epidemiological data not available	f 61 ys (sarcoma type not specified)

Parentheses, number of patients in the respective age group; bold print, number of affected patients; f, female; m, male, ys, years; BCC, basal cell carcinoma. P, two-sided P value in the Chi-square-test; ns, not significant

¹Statistics of basal and squamous cell skin cancers are not reported to and tracked by cancer registries. Data based on mathematical modeling are taken from 48.

cancer of the urinary bladder ($P < 0.04$) and thyroid cancer ($P < 0.01$) (Table 4).

Dataset 1. Raw data supporting the findings in this study

<http://dx.doi.org/10.5256/f1000research.12730.d181450>

Sheet 1, Data for the German patient cohort; Sheet 2, Data for the U.S. patient cohort.

Discussion

It has been shown that MCs can promote tumor development and growth (for references, see *Introduction*). These tumorigenic effects of MCs could be pronounced in MCAD (Table 1), which is characterized by an increased systemic density and activity of MCs. An increased risk for solid cancer has been demonstrated for SM patients³⁸, but MCAS patients have not been investigated in this respect so far.

The present analysis of the frequencies of solid malignancies in the MCAS patients revealed a significantly increased prevalence of melanoma in a subset (male, <50 years) of the German patient group. The more heterogeneous ethnic makeup of the U.S. patient group might be a factor in that group's lower rate of melanoma compared to the Caucasian-only German group, as different ethnic groups might have different risk for melanoma. An increased risk for melanoma has been observed in previous studies with Caucasian SM patients^{38,42–45} with a prevalence of 5% in 81 Swedish SM patients⁴³. It has been speculated that, as in SM, mutations in tyrosine kinase *KIT*, which have also been reported in melanoma^{46,47}, may predispose MCAD patients to melanoma. In addition, the cytokines produced by MCs may recruit melanocytes and stimulate proliferation^{12,43}.

Furthermore, an increased risk for cervical carcinoma, lung and bladder cancer was found in the present study in both the German and U.S. cohorts, and increased risk for breast carcinoma and cancer of the testis was found in the German cohort. The marginal discordances in the type of solid cancers observed in the two groups could be explained by the more heterogeneous ethnic makeup of the U.S. patient group and the limited number of patients included in the study.

It is striking that it is the skin and respiratory and genitourinary tracts – i.e., environmental interfaces – where the increased frequencies were (mostly) seen. Given that (1) MCs preferentially site themselves at the environmental interfaces, (2) MCs have ample capacity to promote local and systemic inflammatory states, and (3) risk for many forms of cancer appears correlated with chronic inflammation, one wonders if the increased risk for these skin and genitourinary tract cancers bears any relationship to the relatively increased density of MCs under normal circumstances in these sites, and thus also potential for greater chronic inflammatory stimulus in these sites.

In the combined study population, intestinal cancer and prostate cancer were as frequent as in the German and U.S. general population. Thus, the reported protective effect of an increased systemic MC activity and density on the development of these two cancer

forms is not observed in our study population who have increased systemic MC activity and density. Our findings are in contrast to data from epidemiological studies suggesting that allergic disease, which is also characterized by increased MC activity, is associated with decreased risk for colorectal cancer (48,49; for review, see 50). It is conceivable that in the present study the ethnic heterogeneity of the combined study population might have masked the expected protective effect⁵¹. In addition, the number of patients included in the present study might still be too low to clearly reveal the purported protective effect.

It is a limitation of the present study that, due to our limited numbers of MCAS patients, we had to partition the patients into only two age groups for each type of cancer for statistical analysis, whereas data from the German and U.S. general populations were partitioned into at least five age groups. However, according to the distribution of the prevalence data within those five groups, it was possible to break them down into two age groups for comparison with our frequency data. Moreover, the reliability of our frequency data is supported by recent similar findings in a Danish MCAD cohort consisting of 687 SM patients³⁸. Unfortunately, it was not possible to compare the frequencies of the solid malignancies determined in our MCAS patient cohorts with those in SM because either the respective frequencies were not reported³⁸ or the MCAD variant of the included patients were not defined exactly (i.e., SM or MCAS)⁵². Moreover, neither of these publications provided the age of the patient at which the cancer occurred. Finally, our German and U.S. cohorts appear to differ in their frequencies of hematologic neoplasms. At present, we could only speculate about reasons for this difference.

In conclusion, our data support the view that MCs may promote development of certain malignancies. These findings indicate a need for increased surveillance of cancers more frequently seen in MCAS patients. Given the influence of inflammation on neoplasia and the chronic multisystem inflammatory state that is the essence of MCAS, it is conceivable that treatment of MCAS (presuming recognition of MCAS in the first place) may reduce risk for neoplasia. It also is possible that treatment of MCAS in the setting of cancer (regardless of whether the MCAS or the cancer is discovered first) may favorably influence the course of the cancer (e.g. 53), similar to the favorable effects often seen when SM is treated in the setting of associated hematologic neoplasia³⁴.

Data availability

Dataset 1: Raw data supporting the findings in this study. Sheet 1, Data for the German patient cohort; Sheet 2, Data for the U.S. patient cohort. doi, [10.5256/f1000research.12730.d181450](https://doi.org/10.5256/f1000research.12730.d181450)⁵⁵

Competing interests

No competing interests were disclosed.

Grant information

Publication was supported by the *Förderclub Mastzellforschung e.V.*, Germany. Collection of the U.S. data was supported by *The Mastocytosis Society*.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary material

Supplementary File 1: Classification of and diagnostic criteria for mast cell activation disease.

[Click here to access the data.](#)

Table S1. WHO criteria defining *Systemic Mastocytosis*

Table S2. Criteria defining *Mast Cell Activation Syndrome*

Table S3. Criteria alternatively proposed to define mast cell activation syndrome

References

- Afrin LB, Butterfield JH, Raihell M, *et al.*: **Often seen, rarely recognized: mast cell activation disease—a guide to diagnosis and therapeutic options.** *Ann Med.* 2016; **48**(3): 190–201.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Molderings GJ, Kolck UW, Scheurlen C, *et al.*: **Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.** *Scand J Gastroenterol.* 2007; **42**(9): 1045–1053.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Molderings GJ, Meis K, Kolck UW, *et al.*: **Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.** *Immunogenetics.* 2010; **62**(11–12): 721–727.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hermine O, Lortholary O, Leventhal PS, *et al.*: **Case-control cohort study of patients' perceptions of disability in mastocytosis.** *PLoS One.* 2008; **3**(5): e2266.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Akin C, Valent P, Metcalfe DD: **Mast cell activation syndrome: proposed diagnostic criteria.** *J Allergy Clin Immunol.* 2010; **126**(6): 1099–104.e4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Haenisch B, Nöthen MM, Molderings GJ: **Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.** *Immunology.* 2012; **137**(3): 197–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cohen SS, Skovbo S, Vestergaard H, *et al.*: **Epidemiology of systemic mastocytosis in Denmark.** *Br J Haematol.* 2014; **166**(4): 521–528.
[PubMed Abstract](#) | [Publisher Full Text](#)
- van Doormaal JJ, Arends S, Brunekreeff KL, *et al.*: **Prevalence of indolent systemic mastocytosis in a Dutch region.** *J Allergy Clin Immunol.* 2013; **131**(5): 1429–31.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Molderings GJ, Haenisch B, Bogdanow M, *et al.*: **Familial occurrence of systemic mast cell activation disease.** *PLoS One.* 2013; **8**(9): e76241.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ribatti D, Ennas MG, Vacca A, *et al.*: **Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma.** *Eur J Clin Invest.* 2003; **33**(5): 420–425.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ribatti D, Vacca A, Ria R, *et al.*: **Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma.** *Eur J Cancer.* 2003; **39**(5): 666–674.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tóth-Jakatics R, Jimi S, Takebayashi S, *et al.*: **Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor.** *Hum Pathol.* 2000; **31**(8): 955–960.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nonomura N, Takayama H, Nishimura K, *et al.*: **Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer.** *Br J Cancer.* 2007; **97**(7): 952–956.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Strouch MJ, Cheon EC, Salabat MR, *et al.*: **Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.** *Clin Cancer Res.* 2010; **16**(8): 2257–2265.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Elpek GO, Gelen T, Aksoy NH, *et al.*: **The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus.** *J Clin Pathol.* 2001; **54**(12): 940–944.
[PubMed Abstract](#) | [Free Full Text](#)
- Iamaroon A, Pongsirivet S, Jittidecharaks S, *et al.*: **Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma.** *J Oral Pathol Med.* 2003; **32**(4): 195–199.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rojas IG, Spencer ML, Martinez A, *et al.*: **Characterization of mast cell subpopulations in lip cancer.** *J Oral Pathol Med.* 2005; **34**(5): 268–273.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Beer TW, Ng LB, Murray K: **Mast cells have prognostic value in Merkel cell carcinoma.** *Am J Dermatopathol.* 2008; **30**(1): 27–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tomita M, Matsuzaki Y, Onitsuka T: **Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma.** *Lung Cancer.* 1999; **26**(2): 103–108.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Welsh TJ, Green RH, Richardson D, *et al.*: **Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.** *J Clin Oncol.* 2005; **23**(35): 8959–8967.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Carlini MJ, Dalurzo MC, Lastiri JM, *et al.*: **Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance.** *Hum Pathol.* 2010; **41**(5): 697–705.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Imada A, Shijubo N, Kojima H, *et al.*: **Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.** *Eur Respir J.* 2000; **15**(6): 1087–1093.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Takanami I, Takeuchi K, Naruke M: **Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma.** *Cancer.* 2000; **88**(12): 2686–2692.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Aaltomaa S, Lipponen P, Papinaho S, *et al.*: **Mast cells in breast cancer.** *Anticancer Res.* 1993; **13**(3): 785–788.
[PubMed Abstract](#)
- Dabiri S, Huntsman D, Makretsov N, *et al.*: **The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis.** *Mod Pathol.* 2004; **17**(6): 690–695.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rajput AB, Turbin DA, Cheang MC, *et al.*: **Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.** *Breast Cancer Res Treat.* 2008; **107**(2): 249–257.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- della Rovere F, Granata A, Familiari D, *et al.*: **Mast cells in invasive ductal breast cancer: different behavior in high and minimum hormone-receptive cancers.** *Anticancer Res.* 2007; **27**(4B): 2465–2471.
[PubMed Abstract](#)
- Xiang M, Gu Y, Zhao F, *et al.*: **Mast cell tryptase promotes breast cancer migration and invasion.** *Oncol Rep.* 2010; **23**(3): 615–619.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ribatti D, Finato N, Crivellato E, *et al.*: **Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases.** *Histopathology.* 2007; **51**(6): 837–842.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nielsen HJ, Hansen U, Christensen JJ, *et al.*: **Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue.** *J Pathol.* 1999; **189**(4): 487–495.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tan SY, Fan Y, Luo HS, *et al.*: **Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer.** *World J Gastroenterol.* 2005; **11**(8): 1210–1214.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

32. Yodavudh S, Tangjitgamol S, Puangsa-art S: **Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer.** *J Med Assoc Thai.* 2008; **91**(5): 723–732.
[PubMed Abstract](#)
33. Elezoglou B, Tolunay S: **The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma.** *Turk Patoloji Derg.* 2012; **28**(2): 110–118.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Acikalin MF, Oner U, Topcu I, *et al.*: **Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas.** *Dig Liver Dis.* 2005; **37**(3): 162–169.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Gulubova M, Vlaykova T: **Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer.** *J Gastroenterol Hepatol.* 2009; **24**(7): 1265–1275.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Fisher ER, Paik SM, Rockette H, *et al.*: **Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01).** *Hum Pathol.* 1989; **20**(2): 159–163.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Johansson A, Rudolfsson S, Hammarsten P, *et al.*: **Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.** *Am J Pathol.* 2010; **177**(2): 1031–1041.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Broesby-Olsen S, Farkas DK, Vestergaard H, *et al.*: **Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study.** *Am J Hematol.* 2016; **91**(11): 1069–1075.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Molderings GJ, Brettner S, Homann J, *et al.*: **Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.** *J Hematol Oncol.* 2011; **4**: 10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Robert Koch-Institut (eds): **Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen zwischen 1990 und 2010. Beiträge zur Gesundheitsberichterstattung des Bundes.** RKI, Berlin, [ISBN 978-3-89606-208-6], 2010.
[Reference Source](#)
41. Howlader N, Noone AM, Krapcho M, *et al.* (eds): **SEER Cancer Statistics Review, 1975–2013.** National Cancer Institute. Bethesda, MD, based on November 2015 SEER data submission, posted to the SEER web site, 2016.
[Reference Source](#)
42. Stern RS: **Prevalence of a history of skin cancer in 2007: results of an incidence-based model.** *Arch Dermatol.* 2010; **146**(3): 279–282.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Hägglund H, Sander B, Gülen T, *et al.*: **Increased risk of malignant melanoma in patients with systemic mastocytosis?** *Acta Derm Venereol.* 2014; **94**(5): 583–584.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Todd P, Garioch J, Seywright M, *et al.*: **Malignant melanoma and systemic mastocytosis—a possible association?** *Clin Exp Dermatol.* 1991; **16**(6): 455–457.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Paolino G, Belmonte M, Trasarti S, *et al.*: **Mast Cell Disorders, Melanoma and Pancreatic Carcinoma: From a Clinical Observation to a Brief Review of the Literature.** *Acta Dermatovenereol Croat.* 2017; **25**(2): 112–119.
[PubMed Abstract](#)
46. Slipicevic A, Herlyn M: **KIT in melanoma: many shades of gray.** *J Invest Dermatol.* 2015; **135**(2): 337–338.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Hung B, Kazo JU, Lundby A, *et al.*: **KIT/D816V induces SRC-mediated tyrosine phosphorylation of the MITF and altered transcription program in melanoma.** *Proceedings of the AACR 107th Meeting.* 2016; **76**(14 Suppl): Abstract 1127.
[Publisher Full Text](#)
48. Sherman PW, Holland E, Sherman JS: **Allergies: their role in cancer prevention.** *Q Rev Biol.* 2008; **83**(4): 339–362.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Negri E, Bosetti C, La Vecchia C, *et al.*: **Allergy and other selected diseases and risk of colorectal cancer.** *Eur J Cancer.* 1999; **35**(13): 1838–1841.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Marech I, Ammendola M, Gadaleta C, *et al.*: **Possible biological and translational significance of mast cells density in colorectal cancer.** *World J Gastroenterol.* 2014; **20**(27): 8910–8920.
[PubMed Abstract](#) | [Free Full Text](#)
51. Hempel HA, Kulac I, Cuka NS, *et al.*: **A relationship between mast cells and the racial disparity of prostate cancer.** *Cancer Epidemiol Biomarkers Prev.* 2016; **25**(Suppl 3): Abstract C73.
[Publisher Full Text](#)
52. Travis WD, Li CY, Bergstralh EJ: **Solid and hematologic malignancies in 60 patients with systemic mast cell disease.** *Arch Pathol Lab Med.* 1989; **113**(4): 365–368.
[PubMed Abstract](#)
53. Afrin LB, Spruill LS, Schabel SI, *et al.*: **Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome.** *Oncology (Williston Park).* 2014; **28**(2): 129–131.
[PubMed Abstract](#)
54. Valent P, Sperr WR, Akin C: **How I treat patients with advanced systemic mastocytosis.** *Blood.* 2010; **116**(26): 5812–5817.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Molderings GJ, Zienkiewicz T, Homann J, *et al.*: **Dataset 1 in: Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA.** *F1000Research.* 2017.
[Data Source](#)

Open Peer Review

Current Referee Status:  

Version 1

Referee Report 30 November 2017

doi:10.5256/f1000research.13790.r28307



Leonard B. Weinstock

Specialists in Gastroenterology, LLC, Washington University School of Medicine, St. Louis, MO, USA

The mast cell (MC) was discovered by **Paul Ehrlich** in 1876. The MC is a unique bone marrow-derived cells since mast cells (MCs) are not found in the blood stream. They are located in tissues of the body where they can reside for many months or years.

The first historical MC path led to the understanding of its role in health. The next path of MC research led to the discovery of the rare, yet well accepted disease mastocytosis - a primary malignant process that had systemic MC-mediator induced symptoms. The next remarkable discovery was that mutations could lead to active MCs and be responsible for over 48 symptoms throughout the body. This confounding presentation of mast cell activation syndrome (MCAS) usually causes confusion and frustration to the physician as well as to the patient. Once MCAS is diagnosed, treatment is often helpful and allows most patients to regain a better quality of life.

The next query posed by Molderings et al is whether or not the MC plays a role in cancer in humans. There are four animal models to suggest that there was a modulating effect in cancer development. Other studies show potential suppression of cancer by MCs. The human connection has been explored in this journal in a large population of MCAS patients. In this study, 828 MCAS were investigated. A history of solid malignant lesions was queried prior to establishing the diagnosis of MCAS.

The authors suggest that this data should be compelling evidence for physicians to perform more intense screening for malignancies in those who have MCAS. The ultimate challenge is to see if modulation, suppression or stabilization of MCs and/or MCAS can decrease the risk and/or progression of cancer.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Referee Expertise: MCAS, RLS, SIBO, IBS, GI

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 21 November 2017

doi:[10.5256/f1000research.13790.r27327](https://doi.org/10.5256/f1000research.13790.r27327)



Bastian Walz

medius Klinik Kirchheim, Vaskulitzentrum Süd, Klinik für Innere Medizin, Rheumatologie und Immunologie, Kirchheim-Teck, Germany

They use very large cohorts for the study.

The authors found an accumulation of hematological neoplasia in the US cohort. This circumstance is probably due to a selection bias, as the attending physician is a haemato-oncologist.

The accumulation of malignant skin tumours could also be caused by a photosensitisation due to mast cell activation disease, as many patients suffer from a rapid skin reaction to UV light.

The present work would be proposed for publication, not least because there are still only a few working groups in this area and there is a strong unmet scientific need for further investigation and information in mast cell activation disease.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research